Related Experiment Video
Updated: Jul 17, 2026
09:38
Generalized Psychophysiological Interaction (PPI) Analysis of Memory Related Connectivity in Individuals at Genetic Risk for Alzheimer's Disease
Published on: November 14, 2017
Apolipoprotein E polymorphism, age and coronary heart disease.
Genovefa D Kolovou1, Katherine K Anagnostopoulou
11st Cardiology Department, Onassis Cardiac Surgery Center, 356 Sygrou Ave., 176 74 Athens, Greece. genovefa@kolovou.com
Ageing Research Reviews
|January 17, 2007
Summary
Apolipoprotein E (apo E) gene variations impact blood lipids and coronary heart disease (CHD) risk. This review examines how apo E influences lipids and CHD onset across different age groups.
Area of Science:
- Cardiovascular Genetics
- Lipid Metabolism
- Atherosclerosis Pathogenesis
Background:
- Plasma lipid and apolipoprotein concentrations are key risk factors for coronary heart disease (CHD).
- Understanding lipid profiles aids in predicting and preventing cardiovascular disease.
- Apolipoprotein E (apo E) gene polymorphism is a common genetic factor influencing blood lipids and CHD.
Purpose of the Study:
- To review the influence of apo E polymorphism on blood lipid levels.
- To analyze the relationship between apo E polymorphism and coronary heart disease (CHD).
- To investigate how these associations vary with age, considering the interplay of genetic and environmental factors.
Main Methods:
- Literature review of studies investigating apo E polymorphism.
- Analysis of data on lipid profiles (lipids, lipoproteins, apolipoproteins) in relation to apo E genotypes.
- Examination of CHD incidence and age of onset in different apo E genotype groups.
Main Results:
- Apo E polymorphism significantly affects plasma concentrations of lipids and lipoproteins.
- Genetic factors, particularly apo E, play a more prominent role in early-onset CHD.
- Environmental factors become more influential in CHD at older ages, potentially modulating the effect of apo E.
Conclusions:
- Apo E polymorphism is a significant genetic determinant in the pathogenesis of atherosclerosis and influences CHD risk.
- The impact of apo E genotype on CHD risk and onset age is age-dependent.
- Targeted lipid management strategies considering apo E genotype may enhance cardiovascular disease prevention.
Related Concept Videos
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:30Coronary Artery Disease I: Introduction
Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:26Coronary Artery Disease IV: Preventive Measures
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
01:26Coronary Artery Disease II: Pathophysiology
Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...